ERBB2 and breast carcinoma: Moreover, a 68Ga-labeled variant of ZHER2:2891, 68Ga-ABY-025, has shown excellent accumulation in metastases with HER2 expression in breast cancer patients, validating its ability for specific targeting of HER2 in a clinical context [25].